Multiplexed iPSCs and immune effector cells targeting solid tumors

JP7863553B2Active Publication Date: 2026-05-21FATE THERAPEUTICS INC
View PDF 3 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
FATE THERAPEUTICS INC
Filing Date
2021-11-04
Publication Date
2026-05-21

AI Technical Summary

Technical Problem

Current adoptive cell therapies using patient-derived and donor-derived cells face challenges in achieving consistent production, efficacy, and persistence of lymphocytes for cancer immunotherapy, particularly in targeting solid tumors, due to issues like cell exhaustion, tumor escape, and immunosuppression.

Method used

Genetically engineered induced pluripotent stem cells (iPSCs) are differentiated to produce immune effector cells with targeted genetic modifications, such as CD34+ cells, that overcome reproducibility and homogeneity issues, enhancing cytotoxicity, persistence, and tumor penetration, using methods like genome editing and reprogramming with inhibitors to introduce specific receptors and suicide genes.

Benefits of technology

The engineered iPSC-derived cells exhibit improved cytotoxicity, persistence, and tumor penetration, reducing immunosuppression and enhancing therapeutic efficacy against solid tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007863553000026
    Figure 0007863553000026
  • Figure 0007863553000027
    Figure 0007863553000027
  • Figure 0007863553000028
    Figure 0007863553000028
Patent Text Reader

Abstract

Methods and compositions are provided for obtaining functionally enhanced induced effector cells obtained from directed differentiation of genomically engineered iPSCs. The iPSC-derived cells provided herein have stable, functional genome editing that results in improved or enhanced therapeutic effects. Therapeutic compositions and uses thereof are also provided, comprising the functionally enhanced induced effector cells alone or in combination with antibodies or checkpoint inhibitors in combination therapy.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Novel t-cell receptor

    WO2019081902A1

  • T cell receptors with MAGE-b2 specificity and uses thereof

    WO2019204683A1

  • CD3 RECONSTITUTION IN ENGINEERED iPSC AND IMMUNE EFFECTOR CELLS

    WO2020210398A1